Abstract

BackgroundAcute promyelocytic leukemia (APL) is characterized by the reciprocal translocation t(15;17), which fuses PML with retinoic acid receptor alpha (RARα). Although PML-RARα is crucially important for pathogenesis and responsiveness to treatment, the molecular and cellular mechanisms by which PML-RARα exerts its oncogenic potential have not been fully elucidated. Recent reports have suggested that long non-coding RNAs (lncRNAs) contribute to the precise control of gene expression and are involved in human diseases. Little is known about the role of lncRNA in APL.MethodsWe analyzed NEAT1 expression in APL samples and cell lines by real-time quantitative reverse transcription-PCR (qRT-PCR). The expression of PML-RARα was measured by Western blot. Cell differentiation was assessed by measuring the surface CD11b antigen expression by flow cytometry analysis.ResultsWe found that nuclear enriched abundant transcript 1 (NEAT1), a lncRNA essential for the formation of nuclear body paraspeckles, is significantly repressed in de novo APL samples compared with those of healthy donors. We further provide evidence that NEAT1 expression was repressed by PML-RARα. Furthermore, significant NEAT1 upregulation was observed during all-trans retinoic acid (ATRA)-induced NB4 cell differentiation. Finally, we demonstrate the importance of NEAT1 in myeloid differentiation. We show that reduction of NEAT1 by small interfering RNA (siRNA) blocks ATRA-induced differentiation.ConclusionsOur results indicate that reduced expression of the nuclear long noncoding RNA NEAT1 may play a role in the myeloid differentiation of APL cells.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-693) contains supplementary material, which is available to authorized users.

Highlights

  • Acute promyelocytic leukemia (APL) is characterized by the reciprocal translocation t(15;17), which fuses PML with retinoic acid receptor alpha (RARα)

  • nuclear enriched abundant transcript 1 (NEAT1) express levels were downregulated in APL Because NEAT1 has been proposed to control several biological processes, including the stress response [21] and cellular differentiation [15], we initially examined the expression level of NEAT1 in peripheral blood mononuclear cells (PBMCs) from 31 cases with de novo APL (13 males and 18 females with a median age of 28.5 years and a range of 17–52 years) expressing the PML-retinoic acid receptor α (RARα) fusion gene, which is characterized by leukemia blasts blocked at the promyelocyte stage of differentiation

  • NEAT1 is suppressed by PML-RARα, and All-trans retinoic acid (ATRA) restores NEAT1 expression The PML-RARα fusion protein is known to be the initiating factor for APL development by transcriptionally repressing retinoic acid and non–retinoic acid target genes, we wondered whether NEAT1 downregulation was a consequence of PML-RARα expression; we investigated the relationship between NEAT1 and PML-RARα

Read more

Summary

Introduction

Acute promyelocytic leukemia (APL) is characterized by the reciprocal translocation t(15;17), which fuses PML with retinoic acid receptor alpha (RARα). Acute promyelocytic leukemia (APL) is characterized by an aberrant chromosomal translocation that fuses a portion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor α (RARα) gene [1], and subsequent expression of the PML-RARα oncoprotein causes a block at the promyelocytic differentiation stage. All-trans retinoic acid (ATRA) has been successfully used as a leukemia therapy to target the transcriptional repression mediated by the PML-RARα fusion protein. The treatment of the t(15;17) APL with ATRA induces the differentiation of PML-RARα is crucially important for pathogenesis and responsiveness to treatment, the mechanism by which PML-RARα exerts its oncogenic potential remains unclear. These data point to the necessity for addressing the issue of indirect PML-RARα-mediated gene expression control

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call